Medicinal composition containing silver ester medicine and ibobulodine

A composition and technology of isosorbide dinitrate, applied in directions such as pharmaceutical combinations, active ingredients of nitro compounds, medical preparations containing active ingredients, etc.

Active Publication Date: 2009-11-04
LUNAN PHARMA GROUP CORPORATION
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

And no effects on glucose or lipid metabolism were found

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition containing silver ester medicine and ibobulodine
  • Medicinal composition containing silver ester medicine and ibobulodine
  • Medicinal composition containing silver ester medicine and ibobulodine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0008] Protective effects of isosorbide mononitrate and ivabradine on chronic myocardial ischemia in rats induced by large doses of isoproterenol Experimental purpose:

[0009] To observe the protective effects of isosorbide mononitrate, ivabradine and their combination on chronic myocardial ischemia induced by high dose isoproterenol in rats.

[0010] experimental method:

[0011] 50 male SD rats were randomly divided into 5 groups, 10 in each group:

[0012] 1. Normal control group: 50 μL / (kg·d) normal saline was injected subcutaneously for 7 days, and 10 mL / (kg·d) normal saline was administered by intragastric administration for 21 days at the same time.

[0013] 2. Model group: subcutaneous injection of isoproterenol 5 mg / (kg·d) to make a chronic myocardial ischemia model for 7 consecutive days; at the same time, intragastric administration of 10 mL / (kg·d) normal saline for 21 consecutive days.

[0014] 3. Isosorbide mononitrate group: Modeling was the same as before, an...

Embodiment 2

[0029] Protective effects of isosorbide mononitrate and ivabradine on chronic myocardial ischemia in minipigs

[0030] Purpose:

[0031] To observe the protective effects of isosorbide mononitrate, ivabradine and their combination on chronic myocardial ischemia in minipigs.

[0032] experimental method:

[0033] About 40 Chinese experimental mini-pigs were taken, and the Ameroid chronic narrowing ring was placed on the proximal end of the left anterior descending coronary artery through thoracotomy. Coronary angiography was performed 5 weeks later, and the anterior descending artery showed obvious stenosis, and the degree of stenosis was selected as 85. From % to 100% of miniature pigs, blood was taken from the large ear vein, and the activities of lactate dehydrogenase (LDH) and creatine kinase MB subtype (CK-MB) in the blood were detected according to the method described in the kit instructions. According to LDH and CK The sum of plasma levels of -MB Miniature pigs were r...

Embodiment 3

[0049] Ivabradine Isosorbide Mononitrate Tablets

[0050] Isosorbide Mononitrate 15g

[0051] Ivabradine 5g

[0052] Starch 50g

[0053] L--HPC 20g

[0054] 10% starch slurry appropriate amount

[0055] Magnesium Stearate 1g

[0056] Preparation Process:

[0057]Pass the isosorbide mononitrate, ivabradine, starch and L-HPC in the prescription through a 100-mesh sieve, mix well, add 10% starch slurry to granulate in an appropriate amount, dry below 50°C, and granulate with a 18-mesh sieve. Add the prescribed amount of magnesium stearate, mix well, and compress into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention proves through a large number of animal experiments that the combined use of ivabradine and nitrate drugs produces remarkable and unexpected effects in the prevention and treatment of myocardial ischemic diseases. Through a large number of animal experiments, we found that the combined use of nitrates and ivabradine had a significant synergistic effect on chronic myocardial ischemia models. Solid preparations prepared together with nitrates and ivabradine, such as tablets, capsules, dispersible tablets, sustained-release tablets, and sustained-release capsules, are dosage forms suitable for clinical use by patients.

Description

technical field [0001] The invention belongs to a new western medicine compound. Background technique [0002] Ivabradine (ivabradine) is one of the most significant advances in the treatment of cardiovascular diseases in the past 20 years. It is the first pure heart rate-lowering factor that acts selectively on the sinoatrial node without affecting intracardiac conduction, myocardial contractility, or ventricular repolarization. Ivabradine is used for the symptomatic treatment of patients with chronic stable angina pectoris who are contraindicated or intolerant of β-blockers and have normal sinus rhythm. This product is the first selective and specific If inhibitor. [0003] Ivabradine showed efficacy and a significant dose-dependent reduction in heart rate, reflecting a reduction in heart rate-systolic blood pressure product that resulted in a reduction in myocardial oxygen consumption. Four double-blind controlled clinical studies involving 3222 patients with chronic s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K9/20A61K9/22A61K9/48A61K9/52A61K31/55A61P9/10A61K31/04A61K31/34
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap